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Survival and prognostic factors in patients with brain metastases
from malignant melanoma
Abstract
AIM: We wanted to determine the factors influencing survival in a retrospective review of patients with
melanoma brain metastases to permit more specific recommendations regarding therapy. PATIENTS
AND METHODS: We reviewed the data of 100 patients treated at the Department of Dermatology and
Radiation Oncology, University of Zurich, and the Klinik im Park, Zurich. Information on potential
prognostic factors (age, sex, location of the primary tumor, Clark level, Breslow index, histological type,
number of brain metastases, stage at initial diagnosis, location of brain metastases, and therapy) was
collected from the medical records of 100 patients treated between 1966 and 2002. Univariate and
multivariate analyses were performed to identify significant prognostic factors. RESULTS: The overall
median survival time was 4.8 months, with 6-month, 1-year and 2-year survival percentages of 36, 14
and 5%, respectively. Univariate analysis indicated that survival correlated significantly with
radiotherapy (partial and whole brain), surgery, stereotactic radiosurgery, chemotherapy, Clark level and
Breslow index. Treatment with temozolomide (p = 0.052) and number of brain metastases (p = 0.07)
failed to be statistically significant. Multivariate analysis confirmed radiotherapy (partial and whole
brain), surgery, stereotactic radiosurgery, chemotherapy and the location of brain metastases as
independent and significant prognostic factors of survival. The remaining factors did not reach statistical
significance in multivariate analysis. CONCLUSION: Radiotherapy, chemotherapy and especially
surgery and stereotactic radiosurgery seem to significantly prolong survival, as shown by multivariate
analysis. Treatment with temozolomide will possibly play an important role in the future management of
patients with brain metastases from cutaneous melanoma, but further prospective studies to verify this
assumption are urgently needed.
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Zusammenfassung
Ziel: In einer retrospektiven Studie an Patienten mit Hirnmetas-
tasen von malignem Melanom wollten wir diejenigen Faktoren
bestimmen, die das Überleben beeinflussen, um therapeuti-
sche Vorschläge formulieren zu können. Patienten und Metho-
den: Die Akten von 100 Patienten der Klinik für Dermatologie
und Radio-Onkologie, Universität Zürich, und der Klinik im
Park, Zürich, wurden ausgewertet. Daten über potentielle pro-
gnostische Faktoren wie Alter, Geschlecht, Lokalisation des Pri-
märtumors, Clark-Level, Breslow-Index, histologischer Typ, An-
zahl der Hirnmetastasen, Stadium bei Erstdiagnose, Lokalisa-
tion der Hirnmetastasen und Therapie wurden aus den Kran-
kengeschichten von 100 Patienten gesammelt, die zwischen
1966 und 2002 behandelt wurden. Univariate und multivariate
Analysen wurden durchgeführt, um die signifikanten prognos-
tischen Faktoren zu bestimmen. Ergebnisse: Die mediane Über-
lebenszeit betrug 4,8 Monate, mit 6-Monats-, 1-Jahres- und 
2-Jahres-Überlebensraten von 36, 14 und 5%. Die univariate
Analyse zeigte, dass das Überleben signifikant mit Radiothera-
pie (Teil- und Ganzhirnbestrahlung), operativer Therapie, stere-
otaktischer Radiochirurgie, Chemotherapie, dem Clark-Level
und Breslow-Index korrelierte. Die Behandlung mit Temozolo-
mid (p = 0,052) und die Anzahl Hirnmetastasen (p = 0,07) waren
nicht signifikant. Die multivariate Analyse bestätigte die Radio-
therapie (Teil- und Ganzhirnbestrahlung), operative Therapie,
stereotaktische Radiochirurgie, Chemotherapie und Lokalisa-
tion der Hirnmetastasen als von einander unabhängige und
signifikante prognostische Faktoren. Die übrigen geprüften Fak-
toren erreichten keine statistische Signifikanz. Schlussfolgerun-
gen: Radiotherapie, Chemotherapie und vor allem die operati-
ve Therapie sowie die stereotaktische Radiochirurgie scheinen
das Überleben signifikant zu verlängern, wie die multivariate
Analyse zeigt. Die Behandlung mit Temozolomid wird in der
Zukunft bei Patienten mit Hirnmetastasen vom kutanen Mela-
nom möglicherweise eine wichtige Rolle spielen, wobei weitere
Studien zur Bestätigung dieser Annahme dringend nötig sind.
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Summary
Aim: We wanted to determine the factors influencing survival in
a retrospective review of patients with melanoma brain metas-
tases to permit more specific recommendations regarding ther-
apy. Patients and Methods: We reviewed the data of 100 pa-
tients treated at the Department of Dermatology and Radiation
Oncology, University of Zurich, and the Klinik im Park, Zurich.
Information on potential prognostic factors (age, sex, location
of the primary tumor, Clark level, Breslow index, histological
type, number of brain metastases, stage at initial diagnosis, lo-
cation of brain metastases, and therapy) was collected from the
medical records of 100 patients treated between 1966 and 2002.
Univariate and multivariate analyses were performed to identify
significant prognostic factors. Results: The overall median sur-
vival time was 4.8 months, with 6-month, 1-year and 2-year sur-
vival percentages of 36, 14 and 5%, respectively. Univariate
analysis indicated that survival correlated significantly with ra-
diotherapy (partial and whole brain), surgery, stereotactic radio-
surgery, chemotherapy, Clark level and Breslow index. Treat-
ment with temozolomide (p = 0.052) and number of brain
metastases (p = 0.07) failed to be statistically significant. Multi-
variate analysis confirmed radiotherapy (partial and whole
brain), surgery, stereotactic radiosurgery, chemotherapy and
the location of brain metastases as independent and significant
prognostic factors of survival. The remaining factors did not
reach statistical significance in multivariate analysis. Conclu-
sion: Radiotherapy, chemotherapy and especially surgery and
stereotactic radiosurgery seem to significantly prolong survival,
as shown by multivariate analysis. Treatment with temozolo-
mide will possibly play an important role in the future manage-
ment of patients with brain metastases from cutaneous
melanoma, but further prospective studies to verify this as-
sumption are urgently needed.
Survival and Prognostic Factors in Patients with Brain
Metastases from Malignant Melanoma
S. Meiera B.G. Baumertb T. Maiera G. Wellisc G. Burga B. Seifertd R. Dummera
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Introduction
Melanoma has a tendency to metastasize to the brain and is
the third most common cause of cerebral metastases in most
series, exceeded only by lung and breast primary sites [1]. As a
result, brain metastases from melanoma are diagnosed in
6–43% of patients and found in 12–74% of deceased patients
[2]. Overall, cerebral metastases indicate a poor prognosis [3].
The natural course without treatment is that of progressive
neurological deterioration with a median survival of only a
few months. Today, a number of different treatment modali-
ties are available and new agents have been introduced, such
as the oral alkylating agent temozolomide. This study was ini-
tiated to define independent factors influencing survival in pa-
tients with brain metastases from cutaneous melanoma so as
to assist clinical decision-making and to help design meaning-
ful prospective randomized studies.
Patients and Methods
The medical records of 100 patients with brain metastases from cutaneous
melanoma treated between 1966 and 2002 at the Departments of Derma-
tology and Radiation Oncology, University of Zurich and the Klinik im
Park, Zurich, were retrospectively reviewed. The brain metastases were
diagnosed with computed tomography (CT) or magnetic resonance ima-
ging (MRI). In 10 cases, diagnosed between 1966 and 1980, the diagnosis
was made based on radioisotope scanning (szintigraphy) and clinical sym-
ptoms only. For each patient, age, sex, location of the primary tumor,
Clark level, Breslow index, histological type, number of brain metastases,
stage at initial diagnosis, location of brain metastases and treatment mo-
dality were recorded. For the analysis of prognostic factors, three age co-
horts were formed: <40 years, 40–60 years and >60 years. Two groups
were formed to describe the location of brain metastases: cerebrum only
and cerebrum combined with other locations (cerebellum, brain stem,
basal ganglia). Because of the small number of patients with Clark levels
I, II and III, these patients were combined in a group and compared to pa-
tients with Clark levels IV and V. Some medical records lacked data for
all examined factors; the missing data were not considered in the statisti-
cal evaluation.
Statistical Methods
Overall survival from the time of diagnosis of brain metastases was calcu-
lated with the Kaplan-Meier method. Univariate analyses were perfor-
med using the Kaplan-Meier method and log rank tests. Multivariate sur-
vival analyses were performed using the Cox proportional hazards model
(stepwise backwards method). 8 factors with p < 0.2 in univariate analysis
were taken into multivariate analysis (Clark level, number of brain meta-
stases, location of brain metastases, radiotherapy, surgery, radiosurgery,
chemotherapy and temozolomide).
Results
Patient Characteristics
A total of 100 patients with brain metastases were evaluated;
the median age of the patient cohort at diagnosis of brain
metastases was 48.7 years (range: 18–80 years). 36 patients
were female and 64 patients were male (table 1). In the major-
ity of patients, the primary tumor was located on the trunk,
followed by the upper extremities. The median interval be-
tween the diagnosis of the primary tumor and brain metas-
tases was 34 months. In 72% of patients with brain metastases,
the primary melanoma reached a Clark level IV or V and in
51% a Breslow index >2.01 mm. 41 patients had a single brain
metastasis (42%); 56 patients had multiple lesions. The brain
metastases were located in the hemispheres in 78 patients
(81%) and were combined with cerebellar, brain stem or basal
ganglia metastases in 18 patients.
71% of patients were suffering from extracranial metastases at
the time brain metastases were detected, and 17% from lymph
node metastases, whereas 12% showed no extracranial metas-
tases. Extracranial metastases were frequently located in the
lungs (75%) followed by the liver (49%). All patients were in
good physical condition, 90% could be treated in an outpa-
tient setting. 
Treatment
All patients received steroids, usually dexamethasone (dose
range 8–60 mg/d, mean 14.9 mg/d), which was tapered out
slowly and eventually discontinued. 54 patients received ra-
diotherapy of the brain (RT). Of these, 35 patients (65%)
were treated with whole brain radiotherapy (WBRT), 12
(22%) with partial brain radiotherapy (PBRT) and 7 (13%)
with PBRT followed by WBRT. The total dose for both
WBRT and PBRT ranged from 12 to 55 Gy (mean 30.1 Gy).
In 17 cases (32%) radiotherapy of the brain was the only ther-
apy, in 20 cases (37%) WBRT was administered after surgery
or stereotactic radiosurgery, in 4 cases (7%) WBRT preceded
surgery or stereotactic radiosurgery (SRS) and in 13 cases
(24%) WBRT was combined with chemotherapy or temozolo-
mide. 37 patients were treated with surgery and 17 patients by
SRS (gamma-knife based in 12 cases (71%), linear-accelerator
based in 5 cases (29%)). The dose of SRS used ranged from 
10 to 22 Gy and was prescribed to the 90, 95 or 100% isodose
encompassing the metastasis for patients treated with a linear
accelerator. Patients treated with a gamma knife received 
20 Gy prescribed at the 50% isodose at the margin of the
metastasis. In 13 cases (24%) surgery or SRS were the only
treatment, in all other cases these therapies were combined
with WBRT and/or chemotherapy. 3 patients received surgery
and 3 patients SRS more than once, 4 patients a combination
of both. In 30 patients (56%) the brain involvement was soli-
tary. In 4 cases (7%) 2 metastases were treated, in 9 cases
(17%) 3 metastases and in 7 cases (13%) more than 3 metas-
tases. In the remaining 4 cases the number of brain metastases
was unknown.
Chemotherapy was given to 38 patients, the most commonly
used agent being DTIC (41%). The number of cycles ranged
from 1 to 6 (mean 2.9 cycles) at a starting dosage of 250
mg/m2/d in the majority of cases. Other substances used in-
cluded cisplatine, oncovine, interferon α and CCNU in various
combinations. A chemotherapy alone was given in 8 cases
(21%).
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Patients, Median survival, 6-Month 1-Year 2-Year p Value
n days (months) survival, % survival, % survival, %
Overall 100 145 (4.8) 36 14 5
Patient characteristics
Age 0.91
<40 31 156 (5.1) 34 14 3
40–60 48 113 (3.7) 34 16 8
>60 21 156 (5.1) 43 10 0
Sex 0.39
Female 36 119 (4.0) 33 11 3
Male 64 165 (5.4) 38 15 6
Location of primary tumor 0.78
Head and neck 11 182 (6.0) 46 18 0
Trunk 38 135 (4.4) 34 14 6
Upper extremity 24 102 (3.4) 29 8 8
Lower extremity 17 97 (3.2) 23 8 0
Clark level 0.048
I–III 19 182 (6.0) 46 18 18
IV–V 48 97 (3.2) 29 10 0
Breslow index 0.013
<1.0 mm 8 176 (5.8) 47 47 23
1.01–2 mm 23 160 (5.3) 44 17 4
2.01–4 mm 19 87 (2.9) 16 – –
>4 mm 13 232 (7.6) 51 9 0
Histological type 0.85
SSM 26 156 (5.1) 41 18 5
Nodular 29 129 (4.2) 33 11 5
LM 2 78 (2.6) 50 50 0
Akrolentiginous 3 118 (3.9) 33 0 0
Undefined 5 31 (1.0) 20 20 0
Number of brain metastases 0.07
1 41 176 (5.8) 49 17 9
>1 56 104 (3.4) 29 12 2
Stage at initial diagnosis 0.57
Local disease 79 143 (4.7) 34 13 4
Nodal metastases 13 167 (5.5) 39 15 0
Visceral metastases 8 77 (2.5) 50 17 17
Location of brain metastases 0.11
Cerebrum only 78 165 (5.4) 39 15 6
Cerebrum and 18 78 (2.6) 27 13 0
other locations
Therapy
WBRT/PBRT 54 166 (5.5) 43 19 6 0.009
No WBRT/PBRT 46 78 (2.6) 28 7 2
Surgery 37 322 (10.6) 62 31 12 <0.0001
No surgery 63 89 (2.9) 21 3 0
Radiosurgery 17 312 (10.3) 71 35 14 0.002
No radiosurgery 83 119 (3.9) 29 9 3
Chemotherapy 38 200 (6.6) 52 25 11 0.001
No chemotherapy 62 102 (3.4) 27 7 0
Temozolomide 17 307 (10.1) 54 29 10 0.052
No temozolomide 83 118 (3.9) 33 11 4
SSM: Superficial spreading melanoma, LM: lentigo maligna, WBRT: whole brain radiotherapy, PBRT: partial brain radio-
therapy.
Table 1. Univariate
analysis
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Temozolomide was administered to 17 patients, the number of cy-
cles ranging from 1 to 6 (mean 2.6 cycles) with a starting dosage of
200 mg/m2/d in the majority of cases. Temozolomide was adminis-
tered in combination with other treatment modalities.
Survival
The overall survival of the 100 patients was 36% at 6 months,
14% at 1 year and 5% at 2 years, with a median survival time
of 4.8 months.
Prognostic Factors
The factors that predicted improved survival by univariate
analysis were the Clark level, Breslow index, radiotherapy
(WBRT/PBRT), surgery, SRS and chemotherapy (table 1 and
fig. 1). Patients with a Breslow index >4 mm survived longest
(median 7.6 months) in our study. In an attempt to define the
reasons why this group lived longest, χ2 tests were performed.
However, no differences in the patient characteristics could
be found between the four groups, with the exception that
chemotherapy was administered more frequently in the group
with an index >4 mm compared to the group with an index of
2.01–4 mm. 
Eight factors with p < 0.2 in univariate analysis were analyzed
by the multivariate proportional hazards model (Clark level,
location of brain metastases, number of brain metastases, ra-
diotherapy, surgery, SRS, chemotherapy, temozolomide). In 
37 medical records data for the Clark level were incomplete,
reducing the number of patients with a complete set of data
for all factors to 63. Therefore, the proportional hazards
model was applied twice, including the Clark level in a first
analysis and excluding this factor in a second. The results are
summarized in table 2. Analyzed factors that are not listed
failed to reach statistical significance.
Discussion
It is well known that prognosis following the development of
intracranial disease from melanoma is poor. In this survey, the
median survival time from diagnosis of cerebral metastases
was 4.8 months and only 4 patients lived for more than 2 years.
This is consistent with other reports, which quote median
overall survival as ranging from 2 to 5 months [4–6]. Despite
this short overall survival, the present study identifies factors
that have an impact on survival: radiotherapy (partial and
whole brain), surgery, radiosurgery, chemotherapy, and brain
metastases located in the hemispheres only. These factors are
associated with an improved survival and remain indepen-
dently and significantly associated with prolonged survival in
multivariate analysis, which is also known from the literature
[7–10]. 
The reported median survival time for patients treated with
radiotherapy or chemotherapy ranges from 2 to 4 months
[11–13], whereas the median survival time for surgery or SRS
ranges from 5 to 22 months [14, 15] and from 8 to 22 months
[16–18], respectively. We found similar ranges for patients
treated with surgery or radiosurgery, and slightly longer medi-
an survival times for radiotherapy of the brain (WBRT/
PBRT) and chemotherapy (5.5 and 6.6 months, respectively).
The combination of WBRT with any form of a local therapy
(surgery or radiosurgery) seems to significantly prolong medi-
an survival in patients with brain metastases from malignant
melanoma independently of the number of metastases [19].
Others could not find a survival advantage for a combined
treatment with WBRT and SRS, if only patients with solitary
metastases are considered [20].
With regard to the remaining prognostic factors analyzed, the
results in other studies vary. All factors tested in this survey
have been shown to have statistically significant influence on
Fig. 1. Kaplan-Meier survival curves for prognostic factors. (a) Chemotherapy received versus not received. (b) Surgery versus no surgery. (c) Radio-
surgery versus no radiosurgery.
Table 2. Multivariate analysis
Patient characteristics Hazard 95% Con-  p Value
ratio fidence limits
Location of brain metastases 
Supratentorial only 0.47 0.26–0.84 0.01
Therapy
WBRT/PBRT 0.45 0.29–0.70 0.0004
Surgery 0.30 0.19–0.49 <0.0001
Radiosurgery 0.31 0.17–0.55 <0.0001
Chemotherapy 0.43 0.27–0.70 0.0006
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survival in at least one other study: age [21], sex [22], location
of the primary tumor [22], Clark level and Breslow index [23],
histological type [23], number of brain metastases [6, 10, 18],
and stage at initial diagnosis [6, 13].
Temozolomide therapy missed statistical significance both in
univariate and multivariate analysis in this survey. However,
significance was only marginally missed (p = 0.052), making it
seem reasonable that in a larger study with a higher number of
patients, significance might be achieved. A recent study com-
paring temozolomide versus dacarbazine in the treatment of
advanced metastatic melanoma, however without cerebral
metastases [24], demonstrated that temozolomide shows equal
efficacy to DTIC. In a further study [25], an increase of 1.1
months in survival in patients treated with temozolomide
compared to patients treated with DTIC was found, although
the difference was not statistically significant.
In conclusion, our retrospective study suggests that patients
receiving either radiotherapy, surgery, radiosurgery or
chemotherapy have a more favorable outlook and achieve
prolonged survival. Patients with supratentorially located
brain metastases are also likely to survive for a longer period
of time. With regard to temozolomide, the results found here
propose that temozolomide might become an effective treat-
ment modality in the future. However, since we cannot ex-
clude a bias in the selection of our patient population and in
the selection of patients who received surgery or stereotactic
radiosurgery, prospective randomized clinical studies are
needed which will address these issues.
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